Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
P Seema. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational psychiatry. vol 6. issue 10. 2017-12-04. PMID:27754480. |
it is concluded that the dopamine partial agonist action of cannabidiol may account for its clinical antipsychotic effects. |
2017-12-04 |
2023-08-13 |
rat |
M A P Bloomfield, E Mouchlianitis, C J A Morgan, T P Freeman, H V Curran, J P Roiser, O D Howe. Salience attribution and its relationship to cannabis-induced psychotic symptoms. Psychological medicine. vol 46. issue 16. 2017-11-16. PMID:27628967. |
we therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. |
2017-11-16 |
2023-08-13 |
Not clear |
E van de Giessen, J J Weinstein, C M Cassidy, M Haney, Z Dong, R Ghazzaoui, N Ojeil, L S Kegeles, X Xu, N P Vadhan, N D Volkow, M Slifstein, A Abi-Dargha. Deficits in striatal dopamine release in cannabis dependence. Molecular psychiatry. vol 22. issue 1. 2017-09-29. PMID:27001613. |
deficits in striatal dopamine release in cannabis dependence. |
2017-09-29 |
2023-08-13 |
human |
E van de Giessen, J J Weinstein, C M Cassidy, M Haney, Z Dong, R Ghazzaoui, N Ojeil, L S Kegeles, X Xu, N P Vadhan, N D Volkow, M Slifstein, A Abi-Dargha. Deficits in striatal dopamine release in cannabis dependence. Molecular psychiatry. vol 22. issue 1. 2017-09-29. PMID:27001613. |
to test whether cannabis dependence is associated with a similar dopaminergic deficit, we examined striatal and extrastriatal dopamine release in severely cannabis-dependent participants (cd), free of any comorbid conditions, including nicotine use. |
2017-09-29 |
2023-08-13 |
human |
Marco Colizzi, Philip McGuire, Roger G Pertwee, Sagnik Bhattacharyy. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. Neuroscience and biobehavioral reviews. vol 64. 2016-12-27. PMID:26987641. |
in fact, it is thought that cannabis or Δ9-thc may not act on dopamine firing directly but indirectly by altering glutamate neurotransmission. |
2016-12-27 |
2023-08-13 |
human |
Silvia Hoirisch-Clapauch, Antonio E Nard. Improvement of Psychotic Symptoms and the Role of Tissue Plasminogen Activator. International journal of molecular sciences. vol 16. issue 11. 2016-09-09. PMID:26593907. |
next, we analyze the role of tpa in the mechanism of action of hormones and medications effective in mitigating psychotic symptoms, such as pregnenolone, estrogen, oxytocin, dopamine d3 receptor antagonists, retinoic acid, valproic acid, cannabidiol, sodium nitroprusside, n-acetyl cysteine, and warfarin. |
2016-09-09 |
2023-08-13 |
Not clear |
Musa Basser Sami, Eugenii A Rabiner, Sagnik Bhattacharyy. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 8. 2016-05-06. PMID:26068702. |
one would thus expect cannabis use to be associated with dopamine signaling alterations. |
2016-05-06 |
2023-08-13 |
human |
Musa Basser Sami, Eugenii A Rabiner, Sagnik Bhattacharyy. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 8. 2016-05-06. PMID:26068702. |
in man, there is as yet little direct evidence to suggest that cannabis use affects acute striatal dopamine release or affects chronic dopamine receptor status in healthy human volunteers. |
2016-05-06 |
2023-08-13 |
human |
Musa Basser Sami, Eugenii A Rabiner, Sagnik Bhattacharyy. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 8. 2016-05-06. PMID:26068702. |
however some work has suggested that acute cannabis exposure increases dopamine release in striatal and pre-frontal areas in those genetically predisposed for, or at clinical high risk of psychosis. |
2016-05-06 |
2023-08-13 |
human |
Musa Basser Sami, Eugenii A Rabiner, Sagnik Bhattacharyy. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 8. 2016-05-06. PMID:26068702. |
furthermore, recent studies are suggesting that chronic cannabis use blunts dopamine synthesis and dopamine release capacity. |
2016-05-06 |
2023-08-13 |
human |
Dardo Tomasi, Gene-Jack Wang, Nora D Volko. Balanced modulation of striatal activation from D2 /D3 receptors in caudate and ventral striatum: Disruption in cannabis abusers. Human brain mapping. vol 36. issue 8. 2016-04-04. PMID:26058801. |
here, we used functional magnetic resonance imaging (fmri) with a sensorimotor reaction time task and positron emission tomography (pet) with [(11)c]raclopride in 14 healthy controls and 18 cannabis abusers to contrast the modulation of striatal fmri responses by dopamine receptors (d2 /d3 r) in cd and vs. |
2016-04-04 |
2023-08-13 |
Not clear |
Matthijs G Bossong, Mitul A Mehta, Bart N M van Berckel, Oliver D Howes, René S Kahn, Paul R A Stoke. Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology. vol 232. issue 15. 2016-02-23. PMID:25801289. |
however, human neurochemical imaging studies that examined the impact of ∆9-tetrahydrocannabinol (thc), the main psychoactive component in cannabis, on striatal dopamine release have provided inconsistent results. |
2016-02-23 |
2023-08-13 |
human |
Omar M E Abdel-Salam, Neveen A Salem, Marwa El-Sayed El-Shamarka, Noha Al-Said Ahmed, Jihan Seid Hussein, Zakaria A El-Khya. Cannabis-induced impairment of learning and memory: effect of different nootropic drugs. EXCLI journal. vol 12. 2015-09-29. PMID:26417227. |
cannabis caused dose-dependent increases of brain serotonin, noradrenaline and dopamine. |
2015-09-29 |
2023-08-13 |
mouse |
Tom G Richardson, Camelia Minica, Jon Heron, Jeremy Tavare, Alasdair MacKenzie, Ian Day, Glyn Lewis, Matthew Hickman, Jacqueline M Vink, Joel Gelernter, Henry R Kranzler, Lindsay A Farrer, Marcus Munafò, David Wynic. Evaluating the role of a galanin enhancer genotype on a range of metabolic, depressive and addictive phenotypes. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 165B. issue 8. 2015-08-28. PMID:25228436. |
initial findings showed a positive relationship of cannabis usage (or = 2.070, p = 0.007, n = 406 (individuals who had used cannabis at least once within the last 12 months, total sample size 2731) with the gg haplotype, consistent with the previous published data linking galanin with an increased release of dopamine. |
2015-08-28 |
2023-08-13 |
human |
Cristina Cadoni, Nicola Simola, Elena Espa, Sandro Fenu, Gaetano Di Chiar. Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats. Addiction biology. vol 20. issue 1. 2015-08-24. PMID:23957273. |
strain dependence of adolescent cannabis influence on heroin reward and mesolimbic dopamine transmission in adult lewis and fischer 344 rats. |
2015-08-24 |
2023-08-12 |
rat |
Robin M Murray, Lucia Sideli, Caterina LA Cascia, Daniele LA Barber. Bridging the gap between research into biological and psychosocial models of psychosis. Shanghai archives of psychiatry. vol 27. issue 3. 2015-08-24. PMID:26300595. |
evidence indicates that both the social risk factors that interest bebbington and biological risk factors, such as abuse of stimulants and cannabis, can provoke psychotic symptoms by dysregulating striatal dopamine. |
2015-08-24 |
2023-08-13 |
Not clear |
David J Nutt, Anne Lingford-Hughes, David Erritzoe, Paul R A Stoke. The dopamine theory of addiction: 40 years of highs and lows. Nature reviews. Neuroscience. vol 16. issue 5. 2015-06-22. PMID:25873042. |
there is robust evidence that stimulants increase striatal dopamine levels and some evidence that alcohol may have such an effect, but little evidence, if any, that cannabis and opiates increase dopamine levels. |
2015-06-22 |
2023-08-13 |
human |
David J Nutt, Anne Lingford-Hughes, David Erritzoe, Paul R A Stoke. The dopamine theory of addiction: 40 years of highs and lows. Nature reviews. Neuroscience. vol 16. issue 5. 2015-06-22. PMID:25873042. |
moreover, there is good evidence that striatal dopamine receptor availability and dopamine release are diminished in individuals with stimulant or alcohol dependence but not in individuals with opiate, nicotine or cannabis dependence. |
2015-06-22 |
2023-08-13 |
human |
Stephanie Mijangos-Moreno, Alwin Poot-Aké, Gloria Arankowsky-Sandoval, Eric Murillo-Rodrígue. Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats. Neuroscience research. vol 84. 2015-06-08. PMID:24800644. |
cannabidiol (cbd) is a constituent of cannabis sativa that promotes wakefulness as well as enhances endogenous levels of wake-related neurotransmitters, including dopamine. |
2015-06-08 |
2023-08-13 |
rat |
Benjamin B Tournier, Nathalie Ginovar. Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 8. 2015-03-30. PMID:24846537. |
here, we investigated the effect of acute and repeated treatment with ∆(9)-tetrahydrocannabinol (thc), the main psychoactive constituent of cannabis, on ppi in rats, and the role of dopamine d₂/₃-receptor blockade in this effect. |
2015-03-30 |
2023-08-13 |
rat |